2014 MPN Challenge Michael Deininger
Michael Deininger, Huntsman Cancer Institute / Department of Hematology and Hematologic Malignancies, University of Utah School of Medicine
Engineering CAR T Cells That Target Mutant CALR as a Novel Therapeutic for Myeloproliferative Neoplasms
CALR Mutation; Immunotherapy
This researcher aims to create an antibody that targets the CALR mutation in the hopes of creating a new treatment for CALR mutant derived MPN. Recently, a treatment was developed for Chronic Lymphocytic Leukemia (CLL). In clinical trials this targeting successfully killed the cells that caused CLL. The hope is to develop something similar for MPN.